title: Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.
authors: Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.
authors: John T
authors: JT
authors: Reilly
authors: Mary Frances
authors: MF
authors: McMullin
authors: Philip A
authors: PA
authors: Beer
authors: Nauman
authors: N
authors: Butt
authors: Eibhlin
authors: E
authors: Conneally
authors: Andrew S
authors: AS
authors: Duncombe
authors: Anthony R
authors: AR
authors: Green
authors: George
authors: G
authors: Mikhaeel
authors: Marie H
authors: MH
authors: Gilleece
authors: Steven
authors: S
authors: Knapper
authors: Adam J
authors: AJ
authors: Mead
authors: Ruben A
authors: RA
authors: Mesa
authors: Mallika
authors: M
authors: Sekhar
authors: Claire N
authors: CN
authors: Harrison
mesh_terms: D000740:Anemia / Q000139:chemically induced; D006801:Humans; D053613:Janus Kinase 1 / Q000037:antagonists & inhibitors*; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors*; D020714:Maximum Tolerated Dose; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines; D012008:Recurrence; D013163:Splenomegaly / Q000188:drug therapy / Q000209:etiology; D063189:Symptom Assessment; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; C507924:JAK2 protein, human; D053613:Janus Kinase 1; D053614:Janus Kinase 2
keywords: CALR; JAK inhibition; myeloproliferative disease